Effects of repurposed drug candidates nitroxoline and nelfinavir as single agents or in combination with erlotinib in pancreatic cancer cells

[1]  Kazuhiro Yoshida,et al.  Curcumin sensitizes pancreatic cancer cells to gemcitabine by attenuating PRC2 subunit EZH2, and the lncRNA PVT1 expression , 2017, Carcinogenesis.

[2]  Fei Zhang,et al.  Sophoridine induces apoptosis and S phase arrest via ROS-dependent JNK and ERK activation in human pancreatic cancer cells , 2017, Journal of Experimental & Clinical Cancer Research.

[3]  Xinyu Huang,et al.  Gambogic acid sensitizes gemcitabine efficacy in pancreatic cancer by reducing the expression of ribonucleotide reductase subunit-M2 (RRM2) , 2017, Journal of experimental & clinical cancer research : CR.

[4]  A. Cama,et al.  Cytotoxic effect of a family of peroxisome proliferator‐activated receptor antagonists in colorectal and pancreatic cancer cell lines , 2017, Chemical biology & drug design.

[5]  R. Mariani-Costantini,et al.  Effects of PPARα inhibition in head and neck paraganglioma cells , 2017, PloS one.

[6]  Dennis P. McDaniel,et al.  Nelfinavir inhibits proliferation and induces DNA damage in thyroid cancer cells. , 2017, Endocrine-related cancer.

[7]  Shou-En Lu,et al.  In vitro comparative studies of resveratrol and triacetylresveratrol on cell proliferation, apoptosis, and STAT3 and NFκB signaling in pancreatic cancer cells , 2016, Scientific Reports.

[8]  James M. Wilson,et al.  ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer , 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[9]  M. A. Satolli,et al.  Current therapeutic strategies for advanced pancreatic cancer: A review for clinicians. , 2016, World journal of clinical oncology.

[10]  C. Chen,et al.  Repurposing of nitroxoline as a potential anticancer agent against human prostate cancer – a crucial role on AMPK/mTOR signaling pathway and the interplay with Chk2 activation , 2015, Oncotarget.

[11]  Shibo Jiang,et al.  Nelfinavir, an HIV protease inhibitor, induces apoptosis and cell cycle arrest in human cervical cancer cells via the ROS-dependent mitochondrial pathway. , 2015, Cancer letters.

[12]  K. Lim,et al.  Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies , 2015, Therapeutic advances in medical oncology.

[13]  S. Steinberg,et al.  A phase I trial of the HIV protease inhibitor nelfinavir in adults with solid tumors , 2014, Oncotarget.

[14]  Jun O. Liu,et al.  Recent Advances in Drug Repositioning for the Discovery of New Anticancer Drugs , 2014, International journal of biological sciences.

[15]  W. Ding,et al.  Nitroxoline (8-hydroxy-5-nitroquinoline) is more a potent anti-cancer agent than clioquinol (5-chloro-7-iodo-8-quinoline). , 2011, Cancer letters.

[16]  Jun O. Liu,et al.  Effect of nitroxoline on angiogenesis and growth of human bladder cancer. , 2010, Journal of the National Cancer Institute.

[17]  T. Chou.  Drug combination studies and their synergy quantification using the Chou-Talalay method. , 2010, Cancer research.

[18]  W. Hohenberger,et al.  Phase I trial of the human immunodeficiency virus protease inhibitor nelfinavir and chemoradiation for locally advanced pancreatic cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  A. Ko,et al.  Erlotinib in the treatment of advanced pancreatic cancer , 2008, Biologics : targets & therapy.

[20]  Robert H. Shoemaker,et al.  Nelfinavir, A Lead HIV Protease Inhibitor, Is a Broad-Spectrum, Anticancer Agent that Induces Endoplasmic Reticulum Stress, Autophagy, and Apoptosis In vitro and In vivo , 2007, Clinical Cancer Research.

[21]  A. Cataldi,et al.  A flow cytometry procedure for simultaneous characterization of cell DNA content and expression of intracellular protein kinase C-zeta. , 2006, Journal of immunological methods.

[22]  Shadan Ali,et al.  Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy , 2005, Molecular Cancer Therapeutics.

[23]  T. Yeatman,et al.  Defining the role of the epidermal growth factor receptor in pancreatic cancer grown in vitro. , 2003, American journal of surgery.

[24]  Masato Nakamura,et al.  Epidermal growth factor receptor expression in human pancreatic cancer: Significance for liver metastasis. , 2003, International journal of molecular medicine.

[25]  M. Youle,et al.  Safety, Pharmacokinetics, and Antiretroviral Activity of the Potent, Specific Human Immunodeficiency Virus Protease Inhibitor Nelfinavir: Results of a Phase I/II Trial and Extended Follow‐up in Patients Infected with Human Immunodeficiency Virus , 1998, Journal of clinical pharmacology.

[26]  M. Mazzanti,et al.  Drug-repositioning opportunities for cancer therapy: novel molecular targets for known compounds. , 2016, Drug discovery today.

[27]  W. Pope,et al.  Nitroxoline induces apoptosis and slows glioma growth in vivo. , 2015, Neuro-oncology.